story of the week
Overall Survival With Neratinib After Trastuzumab-Based Adjuvant Therapy in Patients With HER2+ Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial
Eur. J. Cancer 2023 Mar 01;184(xx)48-59, FA Holmes, B Moy, S Delaloge, SKL Chia, B Ejlertsen, J Mansi, H Iwata, M Gnant, M Buyse, CH Barrios, T Silovski, R Šeparović, A Bashford, AG Zotano, N Denduluri, D Patt, E Gokmen, I Gore, JW Smith, S Loibl, N Masuda, Z Tomašević, K Petráková, D DiPrimeo, A Wong, M Martin, A ChanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.